Pegdinetanib
id:
pegdinetanib-202-1956391
title:
Pegdinetanib
text:
Pegdinetanib is an investigational anti-cancer drug that acts as a selective antagonist of vascular endothelial growth factor receptor 2 (VEGFR-2), hindering vascularization of tumors. It is a genetically engineered peptide derivative based on the monobody technology, and is being developed by Adnexus. The drug has entered Phase II clinical trials investigating the treatment of glioblastoma in October 2007. As of August 2012, it is also in Phase II trials for the treatment of non-small cell lung
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/Pegdinetanib
date created:
date modified:
2023-05-30T01:45:09Z
main entity:
{"identifier":"Q7160603","url":"https://www.wikidata.org/entity/Q7160603"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/e/ed/Pegdinetanib_non-peptide_structure.svg","width":541,"height":183}
fields total:
13
integrity:
15